You are here: Home » Companies » News
Business Standard

Zydus gets USFDA nod to market Tranexamic acid injection

The injection is used to prevent bleeding in patients with hemophilia undergoing tooth extraction


Press Trust of India  |  New Delhi 

Zydus gets USFDA nod to market Tranexamic acid injection

Drug form Cadila today said it has received final nod from the US health regulator to market Tranexamic acid injection.

Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Tranexamic acid injection in the strength of 1,000mg/10 mL (100mg/mL) single dose vial, Cadila Healthcare said in a BSE filing.

The product will be produced at the group's formulations manufacturing facility at Moraiya in Ahmedabad, it added.

The injection is used to prevent or reduce bleeding in patients with hemophilia undergoing tooth extraction, the company said.

The Gujarat-based group has more than 130 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs).

Shares of Cadila Healthcare, the listed entity of the group today closed 3.68 per cent higher at Rs 544.25 per scrip on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, July 19 2017. 19:10 IST